Evaluating whether MaxCyte Inc. (NASDAQ: MXCT) is a good buy or sell requires a detailed look at its financial performance, adoption rates within cell therapy partnerships, and broader biotechnology sector trends. While proponents highlight its tool-and-technology provider business model—which insulates it from single-drug clinical failure by servicing multiple pharma partners—cautious analysts monitor cash burn rates, milestone revenue timelines, and broader macroeconomic valuation pressures.